Package 0069-0342-01

{"route": ["INTRAVENOUS"], "spl_id": "3135aec5-1b5d-4de4-9b73-bfeb7821b75d", "openfda": {"nui": ["N0000193543", "N0000178291", "N0000193542"], "upc": ["0300690342016"], "unii": ["2S9ZZM9Q9V"], "rxcui": ["2268039", "2268044", "2268047", "2268048"], "spl_set_id": ["aa27acbd-d117-4350-aeee-17bc2e2c0ca4"], "pharm_class_epc": ["Vascular Endothelial Growth Factor Inhibitor [EPC]"], "pharm_class_moa": ["Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]", "Vascular Endothelial Growth Factor Inhibitors [MoA]"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01)  / 16 mL in 1 VIAL, SINGLE-USE", "package_ndc": "0069-0342-01", "marketing_start_date": "20200113"}], "brand_name": "Zirabev", "product_id": "0069-0342_3135aec5-1b5d-4de4-9b73-bfeb7821b75d", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]", "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]"], "product_ndc": "0069-0342", "generic_name": "bevacizumab-bvzr", "labeler_name": "Pfizer Laboratories Div Pfizer Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Zirabev", "active_ingredients": [{"name": "BEVACIZUMAB", "strength": "400 mg/16mL"}], "application_number": "BLA761099", "marketing_category": "BLA", "marketing_start_date": "20200113", "listing_expiration_date": "20261231"}